Priveterra Acquisition Corp. (NASDAQ:PMGM) and its biopharmaceutical target, AEON Biopharma, announced this morning that they have secured an additional $20 million in commitments from existing investors in connection to its business combination.
The SPAC brought about $276 million into the deal through its current trust but aside from today’s funding, it has not yet supplemented this with other committed sources of capital. Priveterra must maintain at least $45 million in cash available in order for the deal to close, which means the SPAC potentially still needs to secure an additional $25 million in capital.
Under the terms of the commitments, the issued security is to be exchanged or converted into Class A common stock of the combined company once the proposed merger is completed, and is expected to fund concurrently with or immediately prior to the closing of the deal.
PMGM announced its $201.8 million business combination with drug developer AEON on December 13, 2022. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers.
AEON Biopharma also announced in December the completion of patient enrollment in the Phase 2 study of ABP-450 for the preventive treatment of episodic migraine. The company expects to announce top-line data from the study in the second half of 2023.
Real estate marketplace Opendoor (NASDAQ:OPEN) is poised to be the latest de-SPAC to take a double-digit jump on earnings as it heads towards the weekend up +10%, having spiked as high as +27% earlier in the day. The movement comes as the former Social Capital II target reported progress towards profitability despite a high rates...
At the SPAC of Dawn Coinbase (NASDAQ:COIN) notched a surprise profit of over $1.5 billion in the first quarter of 2024, well exceeding estimates, demonstrating the powerful effect of publicly traded ETFs have had on crypto marketplaces since the start of the year. The result has pushed the company to bump up its own guidance...
Online casino and sports company Rush Street (NYSE:RSI) is up +18.4% in trading today on the back of a solid first quarter earnings release, bringing the company’s stock to its highest price since the second half of 2022 (currently $7.60). This makes it the latest in a line of 2020 and 2021 de-SPACs that have...
Mountain Crest V (NASDAQ:MCAG) broke a long dealmaking silence by SPACs this morning, albeit with a non-binding agreement to combine with Seoul-based diagnostic biotech firm CUBEBIO. The term sheet would give the company a $620 million pre-transaction equity value and help accelerate the rollout of CUBEBIO’s CEED-NOVUS cancer screening kit products. The company signed an...
Churchill Capital Corp IX (NASDAQ:CCIXU) announced the pricing of its $250 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CCIXU”, Thursday, May 2, 2024. The new SPAC will conduct a broad search and has not limited itself to any particular sector or focus, but it plans to...